TKM-Ebola drug has been suspended — 5 notes

TKM-Ebola, a drug used to treat Ebola, has been shelved after showing unsatisfying human trial results in West Africa, according to Cidrap.

Here are five notes:

1. Tekmira Pharmaceuticals has shelved the drug and has opted to focus developing hepatitis B virus treatments.

2. The company will reevaluate its contract with U.S. Department of Defense in light of the TKM-Ebola suspension.

3. Tekmira's press release comes nearly a month after phase 2 trials results in Sierra Leona revealed the drug is unlikely to be beneficial for humans.

4. Some patients exhibited flu-like symptoms in the first phase of the trial.

5. The U.S. Food and Drug Administration put a clinical hold on the drug to analyze the multiple-ascending-dose part of the trial. The FDA later changed its action to allow repeat dosing at a lower dose, which allowed the trial to resume.

More articles on infection control & quality:
68% of visits for acute respiratory infections result in an antibiotic prescription: 6 things to know
Threat of West Nile in New York City: 5 facts to note
Cause for concern: 10 notes on the measles outbreak

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 


Patient Safety Tools & Resources Database

Featured Webinars

Featured Whitepapers

Featured Podcast